NCT00192127已完成3 期
A Prospective, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety of a Bivalent Vaccine of New 6:2 Influenza Virus Reassortants in Healthy Adults
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 300
- 试验地点
- 2
- 主要终点
- The primary endpoint of this study is fever (Day 0-7) defined as oral temperature ³101°F.
研究概览
简要总结
This study is to assess the safety of a bivalent vaccine of two new 6:2 influenza virus reassortants in healthy adults prior to the release of the trivalent vaccine (FluMist) containing them.
详细描述
The primary study objective is to assess the safety of a bivalent vaccine of two new 6:2 influenza virus reassortants in healthy adults prior to the release of the trivalent vaccine (FluMist) containing them. Safety will be demonstrated by similar fever rates (oral temperature ≥101°F Days 0-7) in vaccine and placebo recipients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 49 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •18-49 years of age (not yet reached their 50th birthday);
- •In good health;
- •Available by telephone;
- •Ability to understand and comply with the requirements of the protocol; and
- •Signed informed consent and HIPAA authorization.
排除标准
- •Any condition for which the inactivated influenza vaccine is indicated, including: chronic disorders of the pulmonary or cardiovascular systems, including asthma; chronic metabolic diseases (including diabetes mellitus) renal dysfunction, or hemoglobinopathies which required regular medical follow-up or hospitalization during the preceding year;
- •Acute febrile (>100.0°F oral) and/or respiratory illness, including cough or sore throat, within the 14 days prior to enrollment;
- •Hypersensitivity to egg or egg protein;
- •Hypersensitivity to gentamicin;
- •Any known immunosuppressive condition or immune deficiency disease, including HIV infection, or ongoing immunosuppressive therapy;
- •History of Guillan-Barré Syndrome;
- •Household contact who is immunocompromised (participant should also avoid close contact with immunocompromised individuals for at least 21 days);
- •Participation in another investigational trial within 30 days prior to enrollment or expected enrollment in another investigational trial during this study;
- •Chronic or regular use of antipyretic or analgesic medication on a daily or every other day basis; Notes: A daily dose of 81 mg of aspirin is not considered a contraindication to enrollment. Discontinuation of prophylactic use of antipyretic or analgesic medications at the time of enrollment and for fourteen days following vaccination is not considered a contraindication to enrollment.
- •Pregnancy or, in biologically capable women (e.g., menses within the last year) participant does not agree to use acceptable birth control measures as determined by the investigator continuously for three months after enrolling into the study (for those biologically capable, a urine pregnancy test must be performed on the day of vaccination with a negative result);
- •Breastfeeding or lactating women;
- •Administration of intranasal medications within two weeks prior to enrollment or expected receipt during this study;
- •Employees of the investigational site or their family member or any individuals involved with the conduct of the study; and
- •Any condition that in the opinion of the investigator, might interfere with the vaccine evaluation.
结局指标
主要结局
The primary endpoint of this study is fever (Day 0-7) defined as oral temperature ³101°F.
时间窗: Day 0-7
次要结局
- Secondary endpoints of the study include other reported reactogenicity events and other adverse events that occur within seven days (Day 0-7) and fourteen days (Day 0-14) following vaccination(Days 0-7; 0-14)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
3 期
Study to Evaluate the Safety of a Bivalent Vaccine of New 6:2 Influenza Virus Reassortants in Healthy AdultsHealthyInfluenzaNCT00125944MedImmune LLC300
已完成
3 期
Study To Evaluate the Safety of Bivalent VaccineHealthyNCT00325481MedImmune LLC300
已完成
4 期
A Clinical Study to Assess the Safety of a New Influenza VaccineHealthyNCT01104493MedImmune LLC300
已完成
1 期
A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety and Tolerability of Influenza Virus Vaccine,(CAIV-T) in Healthy InfantsHealthyNCT00192348MedImmune LLC120
已完成
4 期
D2560C00015 FluMist Annual Safety Study 2018HealthyInfluenzaNCT03564444MedImmune LLC300